Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
While published research generally reports favorable tolerability, comprehensive long-term human safety studies have not yet been completed
The trial found that after 5 years, Wegovy significantly reduced the risk of death from heart disease by 15% and reduced the risk of cardiovascular events including nonfatal heart attacks and strokes by 20%, compared to an inactive placebo
31 December 2019
[1] The FDA has issued safety communications regarding compounded semaglutide products, which have been associated with adverse events including overdose due to improper compounding practices and dosing errors
Ikemoto et al., 1997
US$ 20.48
US$ 23.61
US$ 26.20
US$ 20.08
